A. John Rush

Psychiatry University of Texas Southwestern Medical Center, Dallas, TX, United States 
"A. Rush"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Conway CR, Aaronson ST, Sackeim HA, et al. (2024) Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report. Brain Stimulation
Vreijling SR, Chin Fatt CR, Williams LM, et al. (2023) Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials. The British Journal of Psychiatry : the Journal of Mental Science. 1-9
Nandy K, Rush AJ, Carmody T, et al. (2023) A Comparison of Depressive Symptom Self-Reported Measures in the Texas Youth Depression and Suicide Research Network (TX-YDSRN). The Journal of Clinical Psychiatry. 85
Aaronson ST, Sackeim HA, Jiang M, et al. (2023) Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: II. Sensitivity to treatment effects. The Australian and New Zealand Journal of Psychiatry. 48674231209837
Zisook S, Moutier CY, Rush AJ, et al. (2023) Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial. Psychological Medicine. 1-12
Jansen R, Milaneschi Y, Schranner D, et al. (2023) The Metabolome-Wide Signature of Major Depressive Disorder. Research Square
Rush AJ. (2023) Challenges of research on treatment-resistant depression: a clinician's perspective. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 22: 415-417
Haley CL, Kennard BD, Morris DW, et al. (2023) The Quick Inventory of Depressive Symptomatology, Adolescent Version (QIDS-A): A Psychometric Evaluation. Neuropsychiatric Disease and Treatment. 19: 1085-1102
Sackeim HA, Rush AJ, Greco T, et al. (2023) Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life. Psychological Medicine. 1-13
Goodwin GM, Aaronson ST, Alvarez O, et al. (2022) Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. The New England Journal of Medicine. 387: 1637-1648
See more...